このエントリーをはてなブックマークに追加
ID 46848
JaLCDOI
FullText URL
Author
Shien, Tadahiko ORCID Kaken ID publons
Doihara, Hiroyoshi Kaken ID researchmap
Nishiyama, Keiko
Masuda, Hiroko
Nogami, Tomohiro
Ikeda, Hirokuni
Taira, Naruto Kaken ID
Abstract
Combined low-dose therapy of oral capecitabine (Xeloda) and cyclophosphamide (XC) has been demonstrated to be useful for long-term control of lesions in patients with metastatic breast cancer (MBC) and is aimed at symptomatic alleviation and prolongation of survival. Here, a retrospective review was conducted of MBC patients administered XC at the Okayama University Hospital (OUH), to evaluate responses to XC, adverse events and time to progression (TTP). Twenty patients with MBC received XC between 2006 and 2009. With the exception of 2 elderly patients who were over the age of 70 at the initial examination, all of the patients had received prior treatment with an anthracycline and/or a taxane. No complete response (CR) cases were observed, but partial response (PR) was achieved in 6 patients (30%) and SD in 9 (45%), of whom 5 (20%) sustained SD status for >12 months. The median TTP was 6 months (range:3-27 mo.). Three patients developed Grade 3 adverse events (diarrhea, nausea and stomatitis), but no other patients developed adverse reactions causing interruption of the therapy. XC was safe even in previously treated and elderly MBC patients;moreover, it yielded remarkable clinical responses.
Keywords
metastatic breast cancer
metronomic
chemotherapy
Amo Type
Original Article
Published Date
2011-08
Publication Title
Acta Medica Okayama
Volume
volume65
Issue
issue4
Publisher
Okayama University Medical School
Start Page
231
End Page
237
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
Copyright Holders
CopyrightⒸ 2011 by Okayama University Medical School
File Version
publisher
Refereed
True
PubMed ID
Web of Science KeyUT